ACMG 2025

Discover tools and solutions to enable advancements in reproductive health

Please fill out the form below to register for our exhibit theatre presentation or schedule a meeting with our experts to learn more about our latest solutions.

Exhibit theater presentation

Using the Thermo Fisher CytoScan HD Accel Platform
—Duke University’s Experience and Case Study Review

The DUHS Molecular Pathology, Genomics, and Genetics (MPGG) Lab has recently validated and adopted the Applied Biosystem CytoScan HD Accel microarray platform for clinical use. Peripheral blood, cord blood, products of conception (villi and fetal tissue), and bone marrow samples previously analyzed using the CytoScan HD microarray platform were analyzed on the new array as part of the validation, producing 100% concordant results. The CytoScan HD Accel platform presented several advantages: decreased assay turnaround time (TAT), reduced hands-on tech time, lessened DNA input requirements, and improved coverage across the genome. In particular, the accelerated two-day workflow has allowed our lab to implement a new testing schedule with two Cytoscan HD Accel runs per week, instead of one run, providing results within 2-6 days. Please join us for this session to learn more about the significant impact that the CytoScan HD Accel platform brought to our lab.